Cargando…
Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716358/ https://www.ncbi.nlm.nih.gov/pubmed/33256392 http://dx.doi.org/10.3324/haematol.2019.240374 |
| _version_ | 1783619143036043264 |
|---|---|
| author | Zweegman, Sonja Stege, Claudia A.M. Haukas, Einar Schjesvold, Fredrik H. Levin, Mark-David Waage, Anders Leys, Rineke B.L. Klein, Saskia K. Szatkowski, Damian Axelsson, Per Do, Trung Hieu Knut-Bojanowska, Dorota van der Spek, Ellen Svirskaite, Asta Klostergaard, Anja Salomo, Morten Blimark, Celine Ypma, Paula F. Mellqvist, Ulf-Hendrik Poddighe, Pino J. Stevens-Kroef, Marian van de Donk, Niels W.C.J. Sonneveld, Pieter Hansson, Markus van der Holt, Bronno Abildgaard, Niels |
| author_facet | Zweegman, Sonja Stege, Claudia A.M. Haukas, Einar Schjesvold, Fredrik H. Levin, Mark-David Waage, Anders Leys, Rineke B.L. Klein, Saskia K. Szatkowski, Damian Axelsson, Per Do, Trung Hieu Knut-Bojanowska, Dorota van der Spek, Ellen Svirskaite, Asta Klostergaard, Anja Salomo, Morten Blimark, Celine Ypma, Paula F. Mellqvist, Ulf-Hendrik Poddighe, Pino J. Stevens-Kroef, Marian van de Donk, Niels W.C.J. Sonneveld, Pieter Hansson, Markus van der Holt, Bronno Abildgaard, Niels |
| author_sort | Zweegman, Sonja |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7716358 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-77163582020-12-10 Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial Zweegman, Sonja Stege, Claudia A.M. Haukas, Einar Schjesvold, Fredrik H. Levin, Mark-David Waage, Anders Leys, Rineke B.L. Klein, Saskia K. Szatkowski, Damian Axelsson, Per Do, Trung Hieu Knut-Bojanowska, Dorota van der Spek, Ellen Svirskaite, Asta Klostergaard, Anja Salomo, Morten Blimark, Celine Ypma, Paula F. Mellqvist, Ulf-Hendrik Poddighe, Pino J. Stevens-Kroef, Marian van de Donk, Niels W.C.J. Sonneveld, Pieter Hansson, Markus van der Holt, Bronno Abildgaard, Niels Haematologica Letters to the Editor Fondazione Ferrata Storti 2020-02-13 /pmc/articles/PMC7716358/ /pubmed/33256392 http://dx.doi.org/10.3324/haematol.2019.240374 Text en Copyright© 2020 Ferrata Storti Foundation http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letters to the Editor Zweegman, Sonja Stege, Claudia A.M. Haukas, Einar Schjesvold, Fredrik H. Levin, Mark-David Waage, Anders Leys, Rineke B.L. Klein, Saskia K. Szatkowski, Damian Axelsson, Per Do, Trung Hieu Knut-Bojanowska, Dorota van der Spek, Ellen Svirskaite, Asta Klostergaard, Anja Salomo, Morten Blimark, Celine Ypma, Paula F. Mellqvist, Ulf-Hendrik Poddighe, Pino J. Stevens-Kroef, Marian van de Donk, Niels W.C.J. Sonneveld, Pieter Hansson, Markus van der Holt, Bronno Abildgaard, Niels Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial |
| title | Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial |
| title_full | Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial |
| title_fullStr | Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial |
| title_full_unstemmed | Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial |
| title_short | Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial |
| title_sort | ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase ii hovon-126/nmsg 21.13 trial |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716358/ https://www.ncbi.nlm.nih.gov/pubmed/33256392 http://dx.doi.org/10.3324/haematol.2019.240374 |
| work_keys_str_mv | AT zweegmansonja ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT stegeclaudiaam ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT haukaseinar ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT schjesvoldfredrikh ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT levinmarkdavid ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT waageanders ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT leysrinekebl ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT kleinsaskiak ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT szatkowskidamian ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT axelssonper ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT dotrunghieu ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT knutbojanowskadorota ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT vanderspekellen ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT svirskaiteasta ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT klostergaardanja ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT salomomorten ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT blimarkceline ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT ypmapaulaf ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT mellqvistulfhendrik ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT poddighepinoj ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT stevenskroefmarian ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT vandedonknielswcj ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT sonneveldpieter ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT hanssonmarkus ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT vanderholtbronno ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial AT abildgaardniels ixazomibthalidomidelowdosedexamethasoneinductionfollowedbymaintenancetherapywithixazomiborplaceboinnewlydiagnosedmultiplemyelomapatientsnoteligibleforautologousstemcelltransplantationresultsfromtherandomizedphaseiihovon126nmsg2113trial |